Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC +2.58%98 Cash Ratio is 1.32 as of Jun. 2026, which is 89% below its 10-year median of 11.52. GuruFocus rates CHIX:GMABC with a GF Score™ of 98/100 and a GF Value™ of kr2,133.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,382 Biotechnology companies, Genmab AS ranks worse than 67.87% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Genmab AS Cash Ratio Related Terms
Genmab AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for Genmab AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Genmab AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABC) has a Cash Ratio of 1.32 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Genmab AS and its competitors. This is 89% below median its historical median of 11.52. Over the past decade, Genmab AS's Cash Ratio has ranged from 1.20 to 21.99. According to the industry distribution chart, Genmab AS ranks #938 out of 1382 companies in the Biotechnology industry, placing it in the top 67.9%.
Is Genmab AS's Cash Ratio too high?
Genmab AS's current Cash Ratio of 1.32 is 89% below median its 10-year median of 11.52. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 21.99. The Biotechnology industry median Cash Ratio is 2.97. Genmab AS's value of 1.32 is 55.6% below this industry median. Based on the distribution chart, Genmab AS ranks #938 out of 1382 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #938 out of 1382 companies for Cash Ratio. This places Genmab AS in the lower half of its industry. The industry median Cash Ratio is 2.97. Genmab AS's value of 1.32 is 55.6% below this benchmark. Historically, Genmab AS's own Cash Ratio has ranged from 1.20 to 21.99 over the past decade. While the company's 10-year median is 11.52 vs. the industry median of 2.97, Genmab AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Cash Ratio of 1.32 is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Cash Ratio is 1.32, which is 89% below median its own 10-year median of 11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,133.33, compared to a current price of kr2,025.00 — trading 5.1% below its estimated fair value. The current Cash Ratio is 1.32, which is 89% below median its 10-year median of 11.52 and 55.6% below the Biotechnology industry median of 2.97. Genmab AS's overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Cash Ratio is 1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr2,025.00 is trading 5.1% below its estimated GF Value™ of kr2,133.33.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
Cash Ratio: 1.32 (89% below median its 10-year median of 11.52)
GF Value™: kr2,133.33 vs. price of kr2,025.00 (5.1% below fair value)
Industry Position: 55.6% below the Biotechnology median (#938 of 1382)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
98GF Score
Get the complete analysis for CHIX:GMABC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
